Ruti Aga's Six-Year Ban: A March Half Marathon, a Glucocorticoid, and the Forged Sick-Note That Closed Her Only Defence

In March, Ruti Aga crossed the line first at a half marathon in China. The Athletics Integrity Unit's statement on Thursday does not record the time — no splits, no field depth, no winning margin, no weather. What it records is a date: 10 September. That is when her provisional suspension began, and that is where the six-year clock is anchored.

I have spent years standing in the part of a road race the cameras ignore — the corridor past the finish line where athletes in tracksuits wait for an official to hand them a form. I learned to wait in corridors, because the story usually walks past at eye level, not at a podium. And in those corridors you learn that the heaviest document in a marathoner's career is rarely a finishing certificate. Sometimes it is a clinic's prescription slip.

Context: an athlete Ethiopia does not need to replace

Aga is 32. She won the 2026 Tokyo Marathon and finished second in Berlin in 2026 in the region of 2:18:34, part of a record that includes three podium-second finishes at World Marathon Majors. That detail matters because her absence barely touches Ethiopian selection arithmetic. The women's marathon there carries a cohort running under 2:16; a 2:18–2:20 athlete stepping away does not register in the national team's depth chart.

What does register begins with the March sample. An in-competition test returned methylprednisolone. The explanation offered was one that sports medicine recognises immediately: treatment for a knee injury. A prescription was produced. The AIU's investigation found the clinic named on it did not exist; the person who wrote it was a family member with no medical registration, who said he had used an old prescription pad from a former workplace; and the clinic explicitly disowned the document. Three independent verification failures on one page.

The sanction architecture is blunt: two years for presence, four for tampering, six in total, backdated to 10 September.

Core: this is not a steroid case, and the mislabelling is the hinge

International coverage described methylprednisolone as a prohibited steroid. That is technically wrong, and in this case the error is decisive. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9, not an anabolic steroid (S1). And S9 carries a narrow condition: prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection administered out of competition is lawful. It becomes a violation only when residues are still present in-competition. Road-race testing windows open at 23:59 the night before, which is precisely why timing and route decide these cases.

Watching the coverage from a screen taught me which details survive the distance and which ones don't. Here, the word "steroid" travelled into every headline. The word "glucocorticoid" reached none. Readers were handed a fraud story when the underlying case was about route of administration and timing. Aga had a viable defence available: genuine medical records, a documented date and route of injection, and where necessary a therapeutic use exemption application. Handled that way, the presence charge could have been argued at the no-fault or no-significant-fault end, potentially down to a reprimand, with no tampering charge attached at all. Instead the forged document closed the one window that was open from the inside.

The two-plus-four arithmetic is itself information. Two years for presence is the standard outcome where the substance is specified and intent is unproven — but that reduction only arrives if no serious negligence is found. The panel did not grant it. Four years is the Code's standard tampering sanction, and it was applied in full. Backdating to 10 September is procedural housekeeping, not a discount: provisional suspension time counts against the ban.

Contrarian: the penalty lands on the athlete, the system walks

Two things are being skipped.

First, the knee injury, the injection and the informal medical support describe a governance vacuum, not a character flaw. The knee is the load-bearing failure point for high-volume marathoners, and in East African training clusters athletes routinely rely on people who are not credentialed team physicians. The AIU statement names only the family member who wrote the prescription. Where the manager, the agent, or any camp official stood is neither stated nor asked. A forged pad is the cheapest available medical care, and the cheapest available medical care is what an unfunded support structure produces.

Second, the Chinese label-race circuit. Between Majors it has functioned as a lucrative, low-risk income tier for East African marathoners: few races, large appearance fees. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races, and the invoice is being settled by one athlete at a time.

One thing the coverage dropped: results before the violation date are not automatically annulled. The 2026 Tokyo title and those three Major second places remain on the record absent a finding of earlier use. Headlines that folded her into "former winner, now banned" left that out — the same habit that prints the punishment and skips the map.

Takeaway

Six years will expire when she is 38. Against Ethiopia's depth, a 38-year-old returnee with a doping record is unselectable; the 2028 Olympic cycle is already gone. The ban is six years on paper and a career in practice.

The meaningful question is not how strict the AIU was. It is that the enforcement frontier has shifted from detection to document verification — and until federations fund credentialed team physicians inside their squads, the cheapest available medicine will remain a forged prescription, and the athlete holding it will keep paying for everyone who handed it to her.